Literature DB >> 3408638

Saliva and plasma concentrations of isoniazid and acetylisoniazid in man.

A D Hutchings1, R D Monie, B P Spragg, P A Routledge.   

Abstract

1. The pharmacokinetics of isoniazid and acetylisoniazid in plasma and saliva were compared following administration of oral and intravenous doses (200 mg) to healthy volunteers and patients. 2. In the 22 subjects studied after oral administration and the six subjects studied after intravenous administration there was complete phenotypic agreement for both slow (t1/2 greater than 130 min) and fast (t1/2 less than 130 min) acetylators using either saliva or plasma. 3. Acetylator phenotyping based on the t1/2 of INH determined using saliva collected at 2, 3, 4, 5 and 6 h after a 200 mg oral dose appears to be as reliable as that based on plasma. 4. Salivary isoniazid concentrations may provide a non-invasive alternative to plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3408638      PMCID: PMC1386432          DOI: 10.1111/j.1365-2125.1988.tb03349.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Plasma and salivary concentrations of isoniazid in man: preliminary findings in two slow acetylator subjects.

Authors:  H G Boxenbaum; I Berkersky; V Mattaliano; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1975-12

2.  A simple method for determining acetylator phenotype using isoniazid.

Authors:  A Hutchings; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

3.  Pharmacokinetics of tolbutamide: prediction by concentration in saliva.

Authors:  S B Matin; S H Wan; J H Karam
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

4.  High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids.

Authors:  A Hutchings; R D Monie; B Spragg; P A Routledge
Journal:  J Chromatogr       Date:  1983-10-14

5.  A method to prevent the loss of isoniazid and acetylisoniazid in human plasma.

Authors:  A Hutchings; R D Monie; B Spragg; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1983-02       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

  6 in total
  7 in total

1.  The effects of acute ethanol intake on isoniazid pharmacokinetics.

Authors:  R G Dattani; F Harry; A D Hutchings; P A Routledge
Journal:  Eur J Clin Pharmacol       Date:  2004-10-02       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice.

Authors:  Angela A Hwang; Bai-Yu Lee; Daniel L Clemens; Barbara Jane Dillon; Jeffrey I Zink; Marcus A Horwitz
Journal:  Small       Date:  2015-07-20       Impact factor: 13.281

4.  PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.

Authors:  Ankit Balhara; Saranjit Singh
Journal:  Pharm Res       Date:  2021-09-13       Impact factor: 4.200

Review 5.  Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy.

Authors:  Almas Khan; Mohammad Abbas; Sushma Verma; Shrikant Verma; Aliya Abbas Rizvi; Fareya Haider; Syed Tasleem Raza; Farzana Mahdi
Journal:  Glob Med Genet       Date:  2022-02-25

6.  Drug acetylation in breast cancer.

Authors:  D J Webster; D Flook; J Jenkins; A Hutchings; P A Routledge
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

Review 7.  Isoniazid metabolism and hepatotoxicity.

Authors:  Pengcheng Wang; Komal Pradhan; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Acta Pharm Sin B       Date:  2016-08-03       Impact factor: 11.413

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.